| INOZYME INOZYME PHARMA INC.
2147760 29 Jun 2021 | on 28 Feb 2023 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the diagnosis and therapeutic treatment of diseases or disorders afflicting the bone, kidney and tissue, diseases of abnormal mineralization and calcification, diseases of the circulatory system, diseases caused by inborn errors of metabolism, and diseases caused by abnormal intimal proliferation; pharmaceutical products for use in the diagnosis and treatment of bone, kidney and tissue diseases, diseases of abnormal mineralization and calcification, diseases of the circulatory system, diseases caused by inborn errors of metabolism, and diseases caused by abnormal intimal proliferation, none of the aforesaid including pharmaceuticals for use in the treatment of pompe disease. | | | INOZETEK HOI KEUNG LEE
2019698 24 Feb 2020 | on 10 Nov 2021 | Class 012 Class 012 Vehicles and Products for locomotion by land, air or water Pre-designed vinyl vehicle wraps specially adapted for vehicles. | | | INOZYME Inozyme Pharma, Inc.
1885194 27 Feb 2018 | on 29 Sep 2020 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations and substances for use in the diagnosis and treatment of bone diseases; pharmaceutical preparations and substances for use in the diagnosis and treatment of kidney diseases and disorders; pharmaceutical preparations and substances for the treatment and prevention of abnormal mineralization and calcification disorders; pharmaceutical preparations and substances for use in the diagnosis and treatment of tissue diseases and disorders, namely bone disease (rickets), blood vessel (abnormal mineralization of vessels, Intimal Proliferation), kidney(CKD), Skin calcification; pharmaceutical preparations and substances for use in the diagnosis and treatment of circulatory diseases and disorders, namely ENPP1 Deficiency (GACI type I/ARHR2), ABCC6 Deficiency (GACI type II, PXE), Hypopyrophosphatemia and disease of abnormal mineralization of the heart, heart valves, blood vessels, skin, Kidney (hyperphosphaturia, nephrocalcinosis, tubular defects resulting from abnormal phosphorus handling); pharmaceutical preparations and substances for use in the diagnosis and treatment of inborn errors of metabolism, namely ENPP1 Deficiency, ABCC6 Deficiency, Hypopyrophosphatemia; pharmaceutical preparations and substances for use in the diagnosis and treatment of diseases caused by abnormal intimal proliferation; none of the aforesaid including pharmaceuticals for use in the treatment of Pompe disease. | | 
